Recombinant Human VEGF-111b Protein, CF

When Recombinant Human VEGF R2/KDR Fc Chimera (Catalog # 357-KD) is immobilized at 2 µg/mL, Recombinant Human VEGF111b (Catalog # 10036-VE)binds with an ED50 of 12‑72 ng/mL.

2 μg/lane of Recombinant Human VEGF 111b was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing bands at 12 kDa and 33 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human VEGF-111b Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human VEGF R2/KDR Fc Chimera (Catalog # 357-KD) is immobilized at 2 µg/mL (100 µL/well), Recombinant Human VEGF 111b binds with an ED₅₀ of 12-72 ng/mL.
• Source: E. coli-derived human VEGF protein
  Ala27-Arg131, followed by SLTRKD (B isoform, Reference 7)
• Accession #: P15692-1
• N-terminal Sequence: Pro28
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: VEGFA
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 13 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 12 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in HCl.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in 4 mM HCl.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human VEGF-111b Protein, CF

• MVCD1
• VAS
• vascular endothelial growth factor A
• Vascular permeability factor
• Vasculotropin
• VEGF
• VEGFA
• VEGF-A
• VEGFMGC70609
• VPF
• VPFvascular endothelial growth factor

Background

Vascular Endothelial Growth Factor (VEGF or VEGF-A), also known as Vascular Permeability Factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult (1-3). It is a member of the PDGF family that is characterized by the presence of eight conserved cysteine residues and a cystine knot structure (4). Two families of VEGF isoforms are produced through alternative splicing: VEGF xxx (pro-angiogenic) and VEGF xxxb (anti-angiogenic) families that differ by only six amino-acids at the C-terminal end. The B isoform ends with SLTRKD instead of CDKPRR (5). The first verified and widely reported VEGF xxxb family member is VEGF 165b (6). VEGF 111b is a newly discovered member that is induced by UV-B irradiation or by mitomycin C. It doesn't express in normal conditions and has a remarkable resistance to proteolysis (6). Human VEGF 111b shares 87% aa sequence identity with corresponding regions of mouse and rat VEGF. VEGF 111b contains binding domains for VEGF R1 and VEGF R2, however it lacks binding sites for NRP-1 and heparin and cleavage sites for plasmin and matrix metalloproteinases (7, 8). VEGF 111b has been shown to inhibit the proliferation of HUVECs and ovarian cancer cells as well as migration and tube formation of HUVECs (6-7). It has been demonstrated that VEGF 111b functions through VEGF R2 to inhibit the downstream PI3K, Akt, and ERK1/2 signaling pathways (6, 7).

1. Leung, D.W. et al. (1989) Science 246:1306.
2. Keck, P.J. et al. (1989) Science 246:1309.
3. Byrne, A.M. et al. (2005) J. Cell. Mol. Med. 9:777.
4. Robinson, C.J. and Stringer, S.E. (2001) J. Cell. Sci. 114:853.
5. Nowak, D.G. et al. (2008) J. Cell Sci. 121:3487.
6. Li, X. et al. (2015). J.Transl. Med.13:164.
7. Gu, F. et al. (2013) Biochem Biophys Res Commun. 441:18.
8. Dehghanian, F. and Hojati, Z. (2014) Gene 553:57.

FAQs for VEGF (10036-VE). (Showing 1 - 1 of 1 FAQ).

1. Why is the molecular weight of VEGF different from the similar antibody, for some companies the the molecular weight is 40KD)?
   • I can't comment on another company's antibody because I don't have any information about their products. I can tell you that VEGF is expressed in a variety of isoforms and is subject to various post-translational modifications that influence its apparent molecular weight in an SDS-PAGE gel compared to the theoretical molecular weight.

Bioinformatics

• Gene Symbol: VEGFA
• Uniprot:
  • P15692-1()